Ernexa Therapeutics (ERNAW) Interest Coverage Ratio (2015 - 2023)

Ernexa Therapeutics (ERNAW) has 17 years of Interest Coverage Ratio data on file, last reported at 143.33 in Q1 2026.

• Quarterly Interest Coverage Ratio fell 4100.24% year-over-year to 143.33 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 312.26 (down 16681.74% YoY) and the FY2025 annual result came in at 0.36, up 40.82% from the prior year.
• Interest Coverage Ratio retreated to 143.33 in Q1 2026, from 3.19 in the prior quarter.
• In the past five years, Interest Coverage Ratio ranged from a high of 4.06 in Q4 2022 to a low of 143.33 in Q1 2026.
• A 5-year average of 19.52 and a median of 3.93 in 2022 frame the typical range for Interest Coverage Ratio.
• Annual changes were most pronounced in 2022 — Interest Coverage Ratio soared 110.11% — and 2026, when it slumped 4100.24%.
• Tracing ERNAW's Interest Coverage Ratio over 5 years: stood at 4.06 in 2022, then sank by 2352.44% to 91.51 in 2023, then soared by 100.29% to 0.27 in 2024, then slumped by 1294.17% to 3.19 in 2025, then slumped by 4394.9% to 143.33 in 2026.
• The last three Interest Coverage Ratio figures came in at 143.33 (Q1 2026), 3.19 (Q3 2025), and 3.74 (Q2 2025), per Business Quant data.